Simponi 50 mg solution for injection in pre-filled syringe.
Sponsors
Janssen - Cilag International, Janssen Biologics B.V., Universitaetsklinikum Erlangen AöR, Universitair Ziekenhuis Gent, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), IRCCS Istituto Giannina Gaslini
Conditions
Juvenile idiopathic arthritisPeripheral SpondyloarthritisPsoriatic arthritisRheumatoid arthritis according to 2010 criteriaUlcerative Colitis
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
CompletedCTIS2023-507142-83-00
Start: 2019-01-09End: 2025-02-13Target: 7Updated: 2024-11-24
SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling (SPARTACUS).
Active, not recruitingCTIS2023-510085-27-00
Start: 2020-08-21Target: 150Updated: 2025-06-10
Phase 4
PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Not yet recruitingCTIS2024-511530-12-01
Target: 300Updated: 2024-10-01
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
RecruitingCTIS2024-514732-24-00
Start: 2025-04-28Target: 328Updated: 2025-08-26